{"id":300,"date":"2021-08-30T16:43:37","date_gmt":"2021-08-30T20:43:37","guid":{"rendered":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/?p=300"},"modified":"2021-08-30T16:43:37","modified_gmt":"2021-08-30T20:43:37","slug":"federal-circuits-rehearing-decision-confirms-induced-infringement-even-when-skinny-label-was-used","status":"publish","type":"post","link":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2021\/08\/30\/federal-circuits-rehearing-decision-confirms-induced-infringement-even-when-skinny-label-was-used\/","title":{"rendered":"Federal Circuit&#8217;s Rehearing Decision Confirms Induced Infringement Even When Skinny Label Was Used"},"content":{"rendered":"<p>In a recent 2-1 decision after a rehearing, <em>GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc<\/em>., the Federal Circuit confirmed that substantial evidence supported the jury\u2019s findings of induced infringement throughout the term of GSK\u2019s patent, including the \u201cpartial label period\u201d when Teva used a skinny label to carve out a patented method.<\/p>\n<p>To read the full text of this Duane Morris <em>Alert<\/em>, please <a href=\"https:\/\/www.duanemorris.com\/alerts\/federal_circuits_rehearing_decision_confirms_induced_infringement_even_when_skinny_label_0821.html\" target=\"_blank\" rel=\"noopener\">visit the firm website<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In a recent 2-1 decision after a rehearing, GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc., the Federal Circuit confirmed that substantial evidence supported the jury\u2019s findings of induced infringement throughout the term of GSK\u2019s patent, including the \u201cpartial label period\u201d when Teva used a skinny label to carve out a patented method. To read the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2021\/08\/30\/federal-circuits-rehearing-decision-confirms-induced-infringement-even-when-skinny-label-was-used\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Federal Circuit&#8217;s Rehearing Decision Confirms Induced Infringement Even When Skinny Label Was Used&#8221;<\/span><\/a><\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[569,571,568,572,573,560,322,567,570],"ppma_author":[521],"class_list":["post-300","post","type-post","status-publish","format-standard","hentry","category-general","tag-glaxosmithkline","tag-glaxosmithkline-llc-v-teva-pharmaceuticals-usa-inc","tag-gsk","tag-induced-infringement","tag-partial-label","tag-patent-infringement","tag-pharmaceuticals","tag-skinny-label","tag-teva-pharmaceuticals"],"authors":[{"term_id":521,"user_id":6,"is_guest":0,"slug":"duanemorris3","display_name":"Duane Morris","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/843ff6e7a8fe5fc92109b47a45f34b6cf0ea499e6e788db23456c838b0ae6747?s=96&d=blank&r=g","author_category":"1","last_name":"Sullivan","first_name":"Margaret","job_title":"","user_url":"http:\/\/www.duanemorris.com","description":"<a href=\"http:\/\/www.duanemorris.com\">Visit the Duane Morris website.<\/a>"}],"_links":{"self":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/300","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/comments?post=300"}],"version-history":[{"count":0,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/300\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/media?parent=300"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/categories?post=300"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/tags?post=300"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/ppma_author?post=300"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}